HB Wealth Management LLC Purchases 8,406 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

HB Wealth Management LLC grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 46.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 26,411 shares of the biopharmaceutical company’s stock after purchasing an additional 8,406 shares during the quarter. HB Wealth Management LLC’s holdings in Gilead Sciences were worth $2,440,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in GILD. nVerses Capital LLC bought a new position in Gilead Sciences during the 3rd quarter worth approximately $25,000. Valued Wealth Advisors LLC increased its stake in shares of Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 161 shares in the last quarter. Decker Retirement Planning Inc. bought a new stake in shares of Gilead Sciences in the 4th quarter valued at $29,000. Strategic Investment Solutions Inc. IL bought a new stake in shares of Gilead Sciences in the 2nd quarter valued at $33,000. Finally, Quarry LP bought a new stake in shares of Gilead Sciences in the 2nd quarter valued at $43,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ GILD opened at $91.84 on Monday. The company has a market cap of $114.46 billion, a PE ratio of 1,020.44, a price-to-earnings-growth ratio of 1.27 and a beta of 0.18. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $98.90. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The firm’s 50-day simple moving average is $91.75 and its two-hundred day simple moving average is $84.08.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. During the same period in the prior year, the firm earned $2.29 earnings per share. The company’s revenue was up 7.0% compared to the same quarter last year. Research analysts predict that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were given a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 3.35%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is 3,422.22%.

Analyst Ratings Changes

GILD has been the subject of several research analyst reports. Royal Bank of Canada reiterated a “sector perform” rating and issued a $84.00 price objective on shares of Gilead Sciences in a research note on Wednesday, December 11th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Thursday, November 7th. Truist Financial lifted their price objective on shares of Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a research note on Friday, November 8th. Barclays lifted their price target on shares of Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a research report on Thursday, November 7th. Finally, Bank of America reissued a “buy” rating and issued a $109.00 price target on shares of Gilead Sciences in a research report on Tuesday, December 10th. Eleven investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and an average target price of $97.96.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the transaction, the chief financial officer now owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Merdad Parsey sold 25,590 shares of the firm’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the transaction, the insider now directly owns 99,599 shares of the company’s stock, valued at $9,113,308.50. This represents a 20.44 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 456,234 shares of company stock worth $42,130,461. Insiders own 0.29% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.